GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
31 5월 2023 - 8:00PM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout
Semerjian, Chief Executive Officer, will participate in a fireside
chat at the Jefferies Healthcare Conference in New York, NY on
Wednesday, June 7, 2023 at 4:00 p.m. ET.
A live webcast of the fireside chat will be available on the
GlycoMimetics website at
https://ir.glycomimetics.com/investor-relations. An archived
recording will be available for 30 days following the event.
About GlycoMimetics, Inc.
GlycoMimetics is a late clinical-stage biotechnology company
discovering and developing glycobiology-based therapies for
cancers, including AML, and for inflammatory diseases with high
unmet needs. The company’s science is based on an understanding of
the role that carbohydrates play in cell recognition and its
specialized chemistry platform to discover small molecule drugs,
known as glycomimetics, which alter carbohydrate-mediated
recognition in diverse disease states, including cancer and
inflammation. As a leader in this science, GlycoMimetics leverages
this unique approach to advance its pipeline of wholly-owned drug
candidates, with the goal of developing transformative therapies
for diseases with high unmet need. GlycoMimetics is headquartered
in Rockville, MD in the BioHealth Capital Region. Learn more at
www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements. These
forward-looking statements may include, but are not limited to,
statements regarding the conduct of and data from clinical trials,
planned or potential clinical development, regulatory interactions
and submissions, the commercialization and potential benefits and
impact of the Company’s drug candidates, and the Company’s expected
cash runway. Actual results may differ materially from those
described in these forward-looking statements. For a further
description of the risks associated with these statements, as well
as other risks facing GlycoMimetics, please see the risk factors
described in the Company’s Annual Report on Form 10-K filed with
the U.S. Securities and Exchange Commission (SEC) on March 3, 2022,
its Quarterly Report on Form 10-Q filed with the SEC on November 9,
2022, and other filings GlycoMimetics makes with the SEC from time
to time. Forward-looking statements speak only as of the date of
this release, and GlycoMimetics undertakes no obligation to update
or revise these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230531005094/en/
Investors: Argot Partners Leo Vartorella/Collin Beloin
212-600-1902 Glycomimetics@argotpartners.com
GlycoMimetics (NASDAQ:GLYC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
GlycoMimetics (NASDAQ:GLYC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024